Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $11.00 at HC Wainwright
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by HC Wainwright from $12.00 to $11.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 160.05% from the stock’s previous close. HC Wainwright […]
More Stories
Mackenzie Financial Corp Purchases 18,555 Shares of Huntsman Co. (NYSE:HUN)
Mackenzie Financial Corp boosted its stake in Huntsman Co. (NYSE:HUN – Free Report) by 150.2% during the 4th quarter, Holdings...
Promising Battery Technology Stocks To Consider – June 1st
TETRA Technologies, Mullen Automotive, and Platinum Group Metals are the three Battery Technology stocks to watch today, according to MarketBeat’s...
239,417 Shares in Navient Co. (NASDAQ:NAVI) Bought by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Navient Co. (NASDAQ:NAVI – Free Report) in the fourth quarter,...
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Kohl’s Co. (NYSE:KSS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Kohl’s Co. (NYSE:KSS –...
Universal Beteiligungs und Servicegesellschaft mbH Invests $1.73 Million in Evergy, Inc. (NASDAQ:EVRG)
Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Evergy, Inc. (NASDAQ:EVRG – Free Report) during the...
Universal Beteiligungs und Servicegesellschaft mbH Buys New Stake in World Kinect Co. (NYSE:WKC)
Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in World Kinect Co. (NYSE:WKC – Free Report) in the 4th...